NeuroBo Pharmaceuticals Inc NRBO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NRBO is a good fit for your portfolio.
News
-
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
-
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
-
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
-
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
-
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
-
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
-
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
-
NeuroBo Shares Surge as Obesity Drug Moves to Phase I Trial
Trading Information
- Previous Close Price
- $3.08
- Day Range
- $2.99–3.10
- 52-Week Range
- $2.89–6.72
- Bid/Ask
- $0.00 / $7.00
- Market Cap
- $14.77 Mil
- Volume/Avg
- 42,194 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.neurobopharma.com
Valuation
|
Metric
|
NRBO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.89 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NRBO
Financial Strength
|
Metric
|
NRBO
|
|---|---|
Quick Ratio | 3.76 |
Current Ratio | 3.78 |
Interest Coverage | — |
Quick Ratio
NRBO
Profitability
|
Metric
|
NRBO
|
|---|---|
Return on Assets (Normalized) | −53.01% |
Return on Equity (Normalized) | −71.92% |
Return on Invested Capital (Normalized) | −73.81% |
Return on Assets
NRBO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lrtvyhscjg | Pvpkd | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wlxklfv | Gvgfmw | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hjwxpctf | Gvgtmdp | $99.6 Bil | |
MRNA
| Moderna Inc | Rccrhshsx | Qhsg | $38.8 Bil | |
ARGX
| argenx SE ADR | Vnqtzls | Yptr | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Ydwbttlxt | Vdpfh | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dssdnbdt | Lsscff | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kngnncwfd | Grppbzd | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nctbwrwxh | Wbtldq | $12.4 Bil | |
INCY
| Incyte Corp | Gkbgldnh | Pdsmsv | $11.9 Bil |